SG Americas Securities’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$70K Buy
41,463
+9,402
+29% +$13.7K ﹤0.01% 3177
2026
Q1
$42K Sell
32,061
-68,690
-68% -$123K ﹤0.01% 3051
2025
Q4
$188K Buy
100,751
+30,078
+43% +$57.8K ﹤0.01% 2959
2025
Q3
$90K Buy
+70,673
New +$95.7K ﹤0.01% 3107
2025
Q2
– Sell
-32,904
Closed -$39K – 3426
2025
Q1
$39K Buy
32,904
+19,203
+140% +$29.5K ﹤0.01% 3301
2024
Q4
$25K Sell
13,701
-20,007
-59% -$39.1K ﹤0.01% 2996
2024
Q3
$57K Sell
33,708
-8,370
-20% -$13.8K ﹤0.01% 3222
2024
Q2
$58K Buy
42,078
+20,677
+97% +$41.8K ﹤0.01% 2657
2024
Q1
$80K Buy
+21,401
New +$125K ﹤0.01% 2623
2023
Q4
– Sell
-145,614
Closed -$1.22M – 3351
2023
Q3
$1.22M Buy
145,614
+85,988
+144% +$983K 0.01% 1114
2023
Q2
$793K Sell
59,626
-59,343
-50% -$721K 0.01% 1177
2023
Q1
$1.38M Buy
118,969
+41,562
+54% +$413K 0.02% 909
2022
Q4
$633K Buy
77,407
+47,790
+161% +$412K 0.01% 1336
2022
Q3
$172K Sell
29,617
-166,375
-85% -$955K ﹤0.01% 2440
2022
Q2
$866K Buy
+195,992
New +$1.19M 0.01% 1428
2022
Q1
– Sell
-126,676
Closed -$2.59M – 3320
2021
Q4
$2.59M Sell
126,676
-13,614
-10% -$329K 0.01% 890
2021
Q3
$3.58M Buy
140,290
+53,086
+61% +$1.57M 0.02% 767
2021
Q2
$3.05M Sell
87,204
-2,141
-2% -$62.3K 0.01% 861
2021
Q1
$2.98M Sell
89,345
-29,854
-25% -$1.04M 0.02% 784
2020
Q4
$3.09M Buy
+119,199
New +$2.03M 0.02% 809
2020
Q3
– Sell
-11,556
Closed -$40K – 3267
2020
Q2
$40K Sell
11,556
-24,458
-68% -$83.3K ﹤0.01% 3583
2020
Q1
$110K Sell
36,014
-14,810
-29% -$60.6K ﹤0.01% 2944
2019
Q4
$261K Sell
50,824
-575,842
-92% -$2.93M ﹤0.01% 2302
2019
Q3
$3.23M Buy
626,666
+615,461
+5,493% +$3.44M 0.03% 655
2019
Q2
$68K Sell
11,205
-498,017
-98% -$3.49M ﹤0.01% 2887
2019
Q1
$3.68M Buy
509,222
+481,216
+1,718% +$3.48M 0.03% 556
2018
Q4
$207K Buy
+28,006
New +$177K ﹤0.01% 2385
2018
Q2
– Sell
-28,103
Closed -$58K – 3511
2018
Q1
$58K Buy
28,103
+1,566
+6% +$4.07K ﹤0.01% 3075
2017
Q4
$70K Sell
26,537
-92,372
-78% -$323K ﹤0.01% 2944
2017
Q3
$624K Sell
118,909
-3,220
-3% -$13.8K 0.01% 1656
2017
Q2
$435K Buy
122,129
+32,446
+36% +$131K ﹤0.01% 1958
2017
Q1
$464K Buy
89,683
+24,730
+38% +$121K ﹤0.01% 1909
2016
Q4
$247K Sell
64,953
-14,490
-18% -$105K ﹤0.01% 2216
2016
Q3
$712K Buy
79,443
+62,773
+377% +$525K 0.01% 1430
2016
Q2
$117K Sell
16,670
-14,635
-47% -$134K ﹤0.01% 2344
2016
Q1
$266K Buy
31,305
+21,585
+222% +$212K ﹤0.01% 2054
2015
Q4
$128K Buy
+9,720
New +$87.2K ﹤0.01% 2317
2015
Q1
– Sell
-15,603
Closed -$122K – 2966
2014
Q4
$122K Buy
+15,603
New +$100K ﹤0.01% 2790
2014
Q2
– Sell
-21,693
Closed -$116K – 2665
2014
Q1
$116K Sell
21,693
-88,670
-80% -$560K ﹤0.01% 2176
2013
Q4
$577K Sell
110,363
-50,290
-31% -$231K ﹤0.01% 1490
2013
Q3
$888K Buy
160,653
+466
+0.3% +$1.62K ﹤0.01% 1346
2013
Q2
$404K Hold
160,187
– – ﹤0.01% 1361

Other funds holding PACB

SG Americas Securities's PACB Position: Q2 2026 in Review

SG Americas Securities increased its Pacific Biosciences (PACB) stake by 29% in Q2 2026, buying an estimated $13.7K and bringing the position to 41,463 shares worth $70K. The position accounts for ﹤0.01% of the portfolio, ranked #3177.

SG Americas Securities first reported a position in PACB in Q2 2013 and has held it in 42 quarters since. The position peaked at $3.68M in Q1 2019. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • SG Americas Securities held 41,463 shares of Pacific Biosciences worth $70K as of Q2 2026.
  • SG Americas Securities bought 9,402 Pacific Biosciences shares in Q2 2026, an estimated $13.7K.
  • Pacific Biosciences made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #3177 holding.
  • SG Americas Securities first reported a position in Pacific Biosciences in Q2 2013 and has held it in 42 quarters since.
  • SG Americas Securities's Pacific Biosciences position peaked at $3.68M in Q1 2019.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.